DIADIA0.87%
SPYSPY0.60%
QQQQQQ0.49%
Trending
Top trending tickerPLTRPLTR5.17%
TMUSTMUS13.27%
STRKSTRK13.37%
VZVZ8.75%
ONDSONDS1.75%
TT9.81%
MRNAMRNA14.21%
AXSMAXSM0.92%
HIMXHIMX0.30%
PENGUPENGU2.44%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolVTRS
Exchange: NASDAQ·Updated 07:43 PM EDT
VTRS logo

VTRS Viatris Inc

$17.67
$0.20
(1.15%)
Today
Closed $17.64
$0.03
(0.17%)
After Hours
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsNews·Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
EarningsNov 5
Mkt Cap$20.03B
Vol8.83M

About VTRS

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
64

Bullish Sentiment

How do you feel about VTRS?

bradley3
$VTRS Guidance was pushed higher by management. We are heading much higher. Appreciate loading UP at these levels. UP UP UP !!!
2
JFais
Thursday pre-mkt Chat nuggets: $VTRS for $PCRX in the pain space a reminder of the appeal of unsexy areas of drug development $PROF - Playbook setup spiking, but I caution $2.5M of revenue was carried forward from Q2 (supposed to be last week of June) $NKTR - example of extreme swings in sentiment yet thesis intact, POD reversal trade incoming? Real-time Trades Channel, noticing quite a few people paring down to fewer but higher quality holdings to sleep better at night & navigate rough waters $XBI
1
TopTierNewswire
$VTRS - Viatris targets non-opioid pain leadership with a $1.65 billion Pacira $PCRX (for $36.5/share) deal and two patent-protected U.S. brands. Screenshot of recent headlines for Viatris from Top Tier Newswire:
1
StocktwitsNews
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights $VTRS $PCRX $GEHC $BHVN $ALEC https://stocktwits.com/news/equity/markets/stocktwits-biotech-dealmaker-viatris-and-ge-healthcare-buy-what-they-can-sell-biohaven-and-alector-sell-rights/cZxThBFRBnn
topstockalerts
Viatris sued Novo Nordisk in federal court in Delaware, asking a judge to rule that its planned generic version of Wegovy would not infringe Novo Nordisk’s patents. Mylan Pharmaceuticals, a Viatris subsidiary, filed the lawsuit Thursday, seeking a declaration that its generic product would not violate a patent covering Novo’s single-dose Wegovy injection pen for weight-loss treatment. Novo Nordisk generated nearly $31 billion last year from its semaglutide-based weight-loss drugs, Wegovy and Ozempic, according to company reports. Generic versions of the drugs are not expected to enter the U.S. market until 2032, when Novo Nordisk’s patents covering semaglutide, the active ingredient in both treatments, expire. Novo Nordisk has previously reached patent-litigation settlements with Mylan and other drugmakers involving proposed generic versions of Wegovy and Ozempic. $VTRS $NVO
dllydalley29
$VTRS Touched 18 during last earnings...we got a ways to go to get up to TEVA's valuation. Let's go.

Advertisement|Remove ads.

Advertisement|Remove ads.